When 2 biomarkers, Aβ and tau/phosphorylated tau protein, are positively measured, the probability of AD occurrence increases.[7] MRI of medial temporal lobe atrophy, 18FDG-PET of the posterior cingulate and temporoparietal hypometabolism, and amyloid-PET imaging of cortical Aβ deposition are the 3 best-validated neuroimaging biomarkers for AD.[8] Despite insufficient evidence of their clinical practicality, these 3 biomarkers have almost reached analytical and clinical effectiveness. Here, MAPT is linked to Alzheimer disease.